Literature DB >> 33784495

Structural insights into the function of the catalytically active human Taspase1.

Nirupa Nagaratnam1, Silvia L Delker2, Rebecca Jernigan1, Thomas E Edwards2, Janey Snider3, Darren Thifault1, Dewight Williams4, Brent L Nannenga5, Mary Stofega3, Lidia Sambucetti3, James J Hsieh6, Andrew J Flint7, Petra Fromme8, Jose M Martin-Garcia9.   

Abstract

Taspase1 is an Ntn-hydrolase overexpressed in primary human cancers, coordinating cancer cell proliferation, invasion, and metastasis. Loss of Taspase1 activity disrupts proliferation of human cancer cells in vitro and in mouse models of glioblastoma. Taspase1 is synthesized as an inactive proenzyme, becoming active upon intramolecular cleavage. The activation process changes the conformation of a long fragment at the C-terminus of the α subunit, for which no full-length structural information exists and whose function is poorly understood. We present a cloning strategy to generate a circularly permuted form of Taspase1 to determine the crystallographic structure of active Taspase1. We discovered that this region forms a long helix and is indispensable for the catalytic activity of Taspase1. Our study highlights the importance of this element for the enzymatic activity of Ntn-hydrolases, suggesting that it could be a potential target for the design of inhibitors with potential to be developed into anticancer therapeutics.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Ntn-hydrolases; Taspase1; X-ray crystallography; anisotropy; cancer; intrinsically disordered proteins; plant-type L-asparaginases; proteases

Mesh:

Substances:

Year:  2021        PMID: 33784495     DOI: 10.1016/j.str.2021.03.008

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  1 in total

1.  Closantel is an allosteric inhibitor of human Taspase1.

Authors:  Vanessa Luciano; Ewgenij Proschak; Julian D Langer; Stefan Knapp; Jan Heering; Rolf Marschalek
Journal:  iScience       Date:  2021-11-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.